title: Managing HIV. Part 5: Treating secondary outcomes. 5.15 HIV and non-tuberculous mycobacterial infection.
abstract: About one in three patients with advanced immune deficiency will develop disseminated MAC infection. This incidence can be reduced with prophylactic drug therapy, and established infections can be effectively treated, with improved quality of life and lengthened survival.
authors.affiliation: Fairfield Hospital, Melbourne, VIC.
authors.forename: J F
authors.initials: JF
authors.lastname: Hoy
authors.forename: D
authors.initials: D
authors.lastname: Marriott
authors.forename: T
authors.initials: T
authors.lastname: Gottlieb
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000188:drug therapy*; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000904:Antibiotics, Antitubercular / Q000627:therapeutic use; D006801:Humans; D015270:Mycobacterium avium-intracellulare Infection / Q000175:diagnosis / Q000188:drug therapy*; D017828:Rifabutin / Q000627:therapeutic use
chemical_list: D000890:Anti-Infective Agents; D000904:Antibiotics, Antitubercular; D017828:Rifabutin